Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects

Simon Fraser University

$94,417.00

Simultaneous chemotherapy and radiation treatment in solid tumours: A new platform to promote synergy and therapeutic efficacy with radiation triggered drug release

EF 2014-15

Résumé
Treating cancer patients with drugs and radiation at the same time is very effective and even curative, but this combinedtreatment often results in severe toxicities to normal tissues that prevent the treatments from being used at full doses. Wetherefore plan to develop a new platform that uses the radiation treatment to define where and when the drug will act so thatits cytotoxic effects are confined to the tumour site. Nanoscale capsules containing drugs will be designed to have longcirculation times so they accumulate effectively in the tumour. The drug will be efficiently trapped in each capsule tominimize the potential for random toxicities. However, when capsules in the tumour are irradiated, the energy from theradiation will be converted to local heating of the capsules surfaces. The heat generated will melt the capsule, and its drugcontents will be released so we can attain high drug doses only in the tumour; up to 1000 times more in comparison to usingthe drug conventionally. Some drugs (e.g. platinum-based drugs) make cells more vulnerable to radiation so releasing thesedrugs during radiation treatment would enhance cell kill due to radiation. The proposed strategy would ultimately allowdoctors to attain optimal drug and radiation doses with minimal damage to normal tissue. In turn, patients would benefit frommore focused treatments that are potentially curative with fewer toxic side effects. The proposed platform will be designed,produced, tested and evaluated by a purpose-formed multidisciplinary team of senior clinicians with experience in medicaland radiation oncology, and research scientists with experience in nanotechnology, radiation sciences, tumour biology, drugcarrier technologies and other experimental therapeutics. A close partnership with The Centre for Drug Research andDevelopment and Celator Pharmaceuticals will ensure that the technology will reach its full pharmaceutical and commercialpotential.
Programme
Collaborative Health Research Projects
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
462260-2014
Name nom
Gates, Byron
Department département
Chemistry
Organization id
5
Institution établissement
Simon Fraser University
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2014
Award amount
94417
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
1
Nb partie
3
Application title
Simultaneous chemotherapy and radiation treatment in solid tumours: A new platform to promote synergy and therapeutic efficacy with radiation triggered drug release
Keyword
NSERC
Application summary
Treating cancer patients with drugs and radiation at the same time is very effective and even curative, but this combinedtreatment often results in severe toxicities to normal tissues that prevent the treatments from being used at full doses. Wetherefore plan to develop a new platform that uses the radiation treatment to define where and when the drug will act so thatits cytotoxic effects are confined to the tumour site. Nanoscale capsules containing drugs will be designed to have longcirculation times so they accumulate effectively in the tumour. The drug will be efficiently trapped in each capsule tominimize the potential for random toxicities. However, when capsules in the tumour are irradiated, the energy from theradiation will be converted to local heating of the capsules surfaces. The heat generated will melt the capsule, and its drugcontents will be released so we can attain high drug doses only in the tumour; up to 1000 times more in comparison to usingthe drug conventionally. Some drugs (e.g. platinum-based drugs) make cells more vulnerable to radiation so releasing thesedrugs during radiation treatment would enhance cell kill due to radiation. The proposed strategy would ultimately allowdoctors to attain optimal drug and radiation doses with minimal damage to normal tissue. In turn, patients would benefit frommore focused treatments that are potentially curative with fewer toxic side effects. The proposed platform will be designed,produced, tested and evaluated by a purpose-formed multidisciplinary team of senior clinicians with experience in medicaland radiation oncology, and research scientists with experience in nanotechnology, radiation sciences, tumour biology, drugcarrier technologies and other experimental therapeutics. A close partnership with The Centre for Drug Research andDevelopment and Celator Pharmaceuticals will ensure that the technology will reach its full pharmaceutical and commercialpotential.